CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −26,491 | $6.80 | $180K | 830,065 |
| 2025-06-12 | Krebs Andreas Director | Grant or award · Stock Option (Right to Buy) | +75,187 | 75,187 | ||
| 2025-06-12 | Vallone Carol A Director | Grant or award · Stock Option (Right to Buy) | +75,187 | 75,187 | ||
| 2025-06-12 | Bruhn Suzanne Louise Director | Grant or award · Stock Option (Right to Buy) | +75,187 | 75,187 | ||
| 2025-06-12 | CRYSTAL ROGER Director | Grant or award · Stock Option (Right to Buy) | +75,187 | 75,187 | ||
| 2025-06-12 | GRYSKA DAVID W Director | Grant or award · Stock Option (Right to Buy) | +75,187 | 75,187 | ||
| 2025-06-02 | Roberts Brandi Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-03-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −21,208 | $6.74 | $143K | 856,556 |
| 2025-03-25 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 | −6,836 | $6.74 | $46K | 446,177 |
| 2025-03-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −6,576 | $6.74 | $44K | 316,621 |
| 2025-03-25 | Liao Carrie Chief Accounting Officer | Sale 10b5-1 | −2,347 | $6.74 | $16K | 144,923 |
| 2025-03-17 | Wiley Matthew T. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +350,000 | 350,000 | ||
| 2025-03-12 | Barrow Robert Chief Executive Officer | Grant or award | +350,000 | 877,764 | ||
| 2025-03-12 | Karlin Daniel Chief Medical Officer | Grant or award | +115,000 | 453,013 | ||
| 2025-03-12 | Sullivan Mark Chief Legal Officer | Grant or award | +150,000 | 323,197 | ||
| 2025-03-12 | Liao Carrie Chief Accounting Officer | Grant or award | +50,000 | 142,270 | ||
| 2024-12-26 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −19,106 | $7.43 | $142K | 526,666 |
| 2024-12-26 | Liao Carrie Chief Accounting Officer | Sale 10b5-1 | −2,273 | $7.43 | $17K | 97,270 |
| 2024-12-26 | Karlin Dan Chief Medical Officer | Sale 10b5-1 | −6,643 | $7.43 | $49K | 338,013 |
| 2024-12-26 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −4,519 | $7.43 | $34K | 173,197 |
Page 4 of 12 · 225 trades